Showing 4731-4740 of 7004 results for "".
- ARMMS-T2D Study: Metabolic Surgery Outperforms Medical Interventions for Type 2 Diabeteshttps://reachmd.com/news/armms-t2d-study-metabolic-surgery-outperforms-medical-interventions-for-type-2-diabetes/2467153/The 12-year Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes, or ARMMS-T2D, clinical trial continues to provide significant findings on the benefits of bariatric surgery over medical manag
- Olympian Suni Lee Speaks on AD Panelhttps://reachmd.com/news/olympian-suni-lee-speaks-ad-panel/2467107/Gymnast Suni Lee plans to defend her Olympic gold medal this summer in Paris, but first, she took time to participate in a panel discussion on a topic that has plagued her for several years: atopic dermatitis, or eczema. The 21-year-old American joined National Eczema Association President
- Head Injuries in Stunt Performers: Unveiling the Silent Crisishttps://reachmd.com/news/head-injuries-in-stunt-performers-unveiling-the-silent-crisis/2467100/In the heart-pounding action scenes of your favorite blockbuster, it's not always the A-list actor taking the risks but the unsung heroes-;stunt performers-;who bring those breathtaking moments to life. However, behind the glamour lies a grim real
- Eye Exercises to Improve Sight – Is There Any Science Behind Them?https://reachmd.com/news/eye-exercises-to-improve-sight-is-there-any-science-behind-them/2467102/You may have seen advertisements claiming to eliminate the need for eyeglasses through vision therapy or vision training – basically, eye exercises. These exercises include putting pressure on or palming the eye; eye movement exercises; or straining to read by using the wr
- Risk Factors for Long COVID Revealedhttps://reachmd.com/news/risk-factors-for-long-covid-revealed/2467077/NEW YORK, NY (June 14, 2024)--Early in the pandemic, many people who had SARS-Cov-2 infection or COVID-19 began to report that they couldn’t shake off their symptoms even after a month or more—unusually long for a viral infection of the upper re
- Ruxolitinib cream 1.5% Demonstrates Tolerability, Safety Over 52 Weeks in Childrenhttps://reachmd.com/news/ruxolitinib-cream-15-demonstrates-tolerability-safety-over-52-weeks-children/2467044/Ruxolitinib cream 1.5% demonstrated consistently good tolerability and safety over 52 weeks in children 2 to 11 years old with extensive moderate-to-severe atopic dermatitis (AD) in a study presented this month at the Revolutionizing Atopic Dermatitis (RAD) Conference in Chicago, Illinois.
- FDA Approves Adbry Autoinjector for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis (AD)https://reachmd.com/news/fda-approves-adbry-autoinjector-treatment-adults-moderate-severe-atopic-dermatitis-ad/2467043/The FDA has approved LEO Pharma's Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older.1 The new autoinjector (300 mg/2 mL) will provide another option for adult patients in addit
- Study Demonstrates Sustained Reduction in Child Mortality Following Educational Interventions in Low-Resourced Countrieshttps://reachmd.com/news/study-demonstrates-sustained-reduction-in-child-mortality-following-educational-interventions-in-low-resourced-countries/2467027/Mass General Brigham study authors Dr. Phoebe Yager, of Mass General for Children and Dr. Christopher Hartnick of Mass Eye and Ear (center) meet with Dr. Angel Ernesto Alvarado Rodríguez
- Common Sleep Supplement May Be Linked to Lower Risk of Vision Losshttps://reachmd.com/news/common-sleep-supplement-may-be-linked-to-lower-risk-of-vision-loss/2467038/The "sleep hormone" and common supplement melatonin could be linked to a decreased risk of age-related macular degeneration (AMD).AMD is a progressive eye condition affecting the macula, a small area near the centre of the retina, and can blur your central vision.There is
- INTEGUMENT-OLE: Efficacy and Safety of Roflumilast Cream 0.15% in AD Maintained to 56 Weekshttps://reachmd.com/news/integument-ole-efficacy-and-safety-roflumilast-cream-ad-maintained-56-weeks/2467010/Results from the INTEGUMENT-OLE long-term study suggested that roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) is effective and well-tolerated over a treatment period of up to 56 weeks in adults and children aged six years and older. Researchers for the open-label study